**Tabla Suplementaria 1.** Estudios retrospectivos que reportaron elevada proporción de hipertensión arterial (HA), enfermedad cardiovascular (ECV), enfermedad respiratoria crónica (ERC) y estudios prospectivos que evalúan los efectos de los IECA en pacientes con COVID-19.

|  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- |
| **Tipo de Estudio** | **Tamaño muestral** | **Tratados con IECA/BRA** | **Mediana Edad (Años)** | **HTA (%)** | **ECV (%)** | **ERC (%)** | **Referencia** |
| RetrospectivoMulticéntrico552 centros | 1,099 | No |  49 | 15% | 3% | 1% | Guan et al.1 |
| RetrospectivoCentro único | 201 | No | 51 | 19% | 4% | 1% | Wu et al. 2 |
| RetrospectivoDos centros; | 191 | No | 56 | 30% | 8% | 1% | Zhou et al. 3 |
| RetrospectivoDos centros; | 150 | No |  50 | 35% | 9% | 1% | Ruan et al. 4 |
| RetrospectivoCentro único | 140 | No | 57 | 30% | 5% | 1% | Zhang et. 5 |
| RetrospectivoCentro único | 138 | No | 56 | 31% | 14.5% | 1% | Wang et al.6 |
| Multicéntrico7 centros | 62 | No | 41 | 8% | 2% | 2% | Xu et al. 7 |
| RetrospectivoCentro único | 41 | No |  49 | 15% | 15% | No | Huang et al.8 |
| Revisión sistemática | 46,248 | No | 46 | 17% | 5% | No | Yang et al.9 |
| Ensayo clínico controlado aleatorio | 580\* | BRALosartán; 25 mg | Mayor de 18 | N/A | N/A | N/A | ClinicalTrials.gov identificador: NCT0431117710 |
| Ensayo clínico controlado aleatorio | 200\*\* | BRALosartán; 50 mg | Mayor de 18 | N/A | N/A | N/A | ClinicalTrials.gov identificador: NCT0431200911 |

\*Pacientes que no requieren hospitalización \*\* Pacientes que requieren hospitalización

Referencias bibliográficas

1. Guan W-j*, et al.* Clinical Characteristics of Coronavirus Disease 2019 in China. New England Journal of Medicine 2020. <https://doi.org/10.1056/NEJMoa2002032>

2. Wu C*, et al.* Risk Factors Associated With Acute Respiratory Distress Syndrome and Death in Patients With Coronavirus Disease 2019 Pneumonia in Wuhan, China. JAMA Internal Medicine 2020. <https://doi.org/10.1001/jamainternmed.2020.0994>

3. Zhou F*, et al.* Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet 2020;**395**: 1054-1062. [https://doi.org/10.1016/s0140-6736(20)30566-3](https://doi.org/10.1016/s0140-6736%2820%2930566-3)

4. Ruan Q, Yang K, Wang W, Jiang L, Song J. Clinical predictors of mortality due to COVID-19 based on an analysis of data of 150 patients from Wuhan, China. Intensive Care Med 2020. <https://doi.org/10.1007/s00134-020-05991-x>

5. Zhang JJ*, et al.* Clinical characteristics of 140 patients infected with SARS-CoV-2 in Wuhan, China. Allergy 2020. <https://doi.org/10.1111/all.14238>

6. Wang D*, et al.* Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus-Infected Pneumonia in Wuhan, China. Jama 2020. <https://doi.org/10.1001/jama.2020.1585>

7. Clinical findings in a group of patients infected with the 2019 novel coronavirus (SARS-Cov-2) outside of Wuhan, China: retrospective case series. Bmj 2020;**368**: m792. <https://doi.org/10.1136/bmj.m792>

8. Huang C*, et al.* Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet 2020;**395**: 497-506. [https://doi.org/10.1016/s0140-6736(20)30183-5](https://doi.org/10.1016/s0140-6736%2820%2930183-5)

9. Yang J*, et al.* Prevalence of comorbidities in the novel Wuhan coronavirus (COVID-19) infection: a systematic review and meta-analysis. Int J Infect Dis 2020. <https://doi.org/10.1016/j.ijid.2020.03.017>

10. Medicine CgIBMNLo, (US). Losartan for Patients With COVID-19 Not Requiring Hospitalization. (ed^(eds) (March 17, 2020).

11. Medicine CgIBMNLo, (US). Losartan for Patients With COVID-19 Requiring Hospitalization. (ed^(eds) (2020).